Mechanisms of Cytokine-Induced Glioma Immunosuppression

Alexander Ksendzovsky1, Roberta P. Glick2, Paul Polak3, Maria-Vittoria Simonini3, Anothony J. Sharp3, Tyler Newman5 Edward P. Cohen4 and Douglas L. Feinstein3

1Chicago Medical School, North Chicago, IL, USA; 2Mt. Sinai Hospital Dept. Neurosurgery, Rush College of Medicine Dept. Neurosurgery, University of Illinois - Chicago Dept. Anatomy and Cell Biology, Chicago, IL, USA; 3University of Illinois – Chicago Dept. Anesthesia, Jesse Brown Veterans Affair Hospital, Chicago, IL, USA, 4UIC Dept. Microbiology and Immunology, Chicago, IL, USA

Abstract: Glioma immunosuppression includes the secretion of cytokines that down-regulate the host immune response resulting in tumor survival. The mechanisms of cytokine-induced immunosuppression are not well understood and are considered in this study. Glioma cells were incubated with supernatant from activated and naïve T-cells. A separate culture of T-cells (naïve, CD3-activated, and CD3/CD28 activated) was then incubated with conditioned media from the treated glioma cells as well as individual and combination recombinant cytokines. These T-cells were tested for viability, proliferation and IFN-γ release. Several conclusions were drawn from these experiments: cytotoxicity is not a means of glioma immunosuppression, glioma conditioned media decreases proliferation of CD3/CD28 activated T-cells acting potentially through IL10 and IGFBP, and these cytokines also decrease IFN-γ secretion from all varieties of T-cells suggesting that T-cell differentiation away from TH1 is another potential means of immunosuppression. These results necessitate further analysis of proliferation and differentiation as potential mechanisms of immunosuppression and the incorporation of this knowledge into the production of a more efficacious tumor vaccine.

Key Words: Glioma, immunotherapy, cytokine, TGF-beta, immunosuppression.

INTRODUCTION

Gliomas have evolved several mechanisms to evade host immunity leading to enhanced tumor proliferation and limited immunotherapy effectiveness. For the last two decades, several immunosuppressive mechanisms have been explored including T-regulatory cells, immunosuppressive cytokines, antigen down-regulation, and immune-inhibitory molecules [1-3], yet no definitive conclusions have been reached. IL-10, TGF-β, PGE, and other cytokines have recently been implicated in direct immune-suppression [4-8]. Research has shed some light on cytokines’ mechanisms of immunosuppression including the following: TGF-β2 has been found to inhibit cytotoxic responses of T cells, IL-10 down-regulates MHC Class II expression and suppresses T cell proliferation [5-7]; PGE2 was shown to regulate the initiation of an immune response, and VEGF inhibits the maturation of dendritic cells (DCs) and down-regulates MHC class II molecules [4, 8]. Despite these promising results there is still much left to be discovered regarding mechanisms of cytokine-induced immunosuppression and this is the topic of our study.

In the present study we explored the potential mechanisms of immunosuppression from a collective sample of cytokines secreted by mouse glioma cells in response to activated immunity. Activated immunity was simulated by incubating glioma cells with conditioned media from T-cells activated with anti-CD3/CD28 antibodies. The glioma supernatant, containing cytokines secreted by glioma in response to T-cell CM, was then removed and incubated with separate T-cells. Three variants of T-cells including naïve T-cells, CD3 activated T-cells, and CD3/CD28 activated T-cells were compared and tested for cytotoxic effects, proliferation and IFN-γ release (as a measure for potential differentiation). We also performed the above tests on individual and combinations of recombinant cytokines incubated with T-cells including IL-10, TGF-β1, IGFBP.

MATERIALS AND METHODOLOGY

Cell Lines and Experimental Animals

The GL261 cell line, a glial tumor cell line of C57B16 mouse origin, was obtained from the National Cancer Institute, Frederick Cancer Research and Development Center. The cells were passaged in vitro in Dulbecco modified Eagle medium (Mediatech) containing 25 mM glucose and supplemented with 10% fetal bovine serum (Gibco) and antibiotics. The medium was changed every 3 days.

T-cell Isolation and Activation

For T cell isolation, 2 spleens were isolated from adult C57B16 mice. The spleens were manually homogenized in PBS and the morcellate was centrifuged at 1000 rpm for 5 minutes to obtain cells. The supernatant was discarded and the pellet was resuspended in 3 mL of red cell lysis buffer at room temperature for 5 minutes. Additional 7 mL PBS was added and the cells were again centrifuged at 1000 RPM for 5 minutes to obtain leukocytes in pellet. The pellet was resuspended in serum free DMEM to 10 mL, counted, and
plated at a final density of 2E6 cells/mL in a 24 well plate. The T-cells were then incubated with anti-CD3 and anti-CD28 antibody for 24 hours in the following concentrations: 0.2ug/mL and 0.5ug/mL. Supernatant from T cells activated by anti-CD3/CD28 was used as activated TCM. Supernatant from naïve T-cells was collected and used as naïve TCM. The TCM (active and naïve) was used to treat glioma cells for 24 hr. Supernatant was then collected from the glioma cells and was used to treat a separate group of T-cells in culture. The T-cells were divided into three groups: naïve, CD3-treated, and CD3/CD28 treated cells and each group was treated with supernatant from glioma cells treated with either CD3/28 activated T-cell media or naïve T-cell media. After 24 hrs of treatment, these cells were then tested for LDH release (cytotoxicity), for proliferation via a BrdU colorimetric assay, and IFN-γ production (see Fig. 1 for flowchart of study).

LDH Cytotoxicity Assay

T-cells were treated with either supernatant from glioma cells (GCM) that had been treated with either activated or inactivated T-cell CM at either 5% or 20% final dilution, or with recombinant TGF-β1, IL-10, IGFBP, and IL-10/IGFBP at the following concentrations: 5, 10, and 20 ng/mL. After 24 hr, aliquots of the T-cell media were assayed for LDH release according to the recommended protocol from Promega’s CytoTox 96 Non-Radioactive Cytotoxicity assay. In brief, the plates were spun at 500 RPM and 50uL of supernatant was taken from each well and placed into a 96-well plate in triplicate. Substrate was then added and absorbance was measured at 492nm.

BrdU Proliferation Assay

T-cell proliferation was measured using a BrdU proliferation assay on the previously mentioned T-cell groups comparing nGCM to aGCM as well as recombinant IL-10/IGFBP. The GCM treated T-cells were compared to a control of T-cells treated with 1% FBS while the recombinant cytokine treated cells were compared to untreated T-cells. These cells were plated in 96-well plates and the recommended protocol of the Colorimetric BrDU Proliferation assay from Roche was applied. Briefly, after treatments with GCM or recombinant cytokines for 24 hr, Brdu was added and cells allowed to grow for a further 24 hr. The cells were then dried and fixed to the bottom of the well, treated with anti-BrdU antibody conjugated with horseradish peroxidase, and then treated with substrate. Absorbance was then measured at 450nm with a reference wavelength of 620nm. The BrdU proliferation assay was performed in quadruplicate.

T-cell IFN-γ secretion - ELISA

After indicated treatments, aliquots of the T-cell media were assayed for levels of IFN-γ by ELISA following recommended procedures (Quantikine M, R&D Systems, Minneapolis, MN). Each sample was assayed at least in duplicate. calculation of ng/mL cytokine determined from standard curves, and the differential secretion from T-cells from all conditions was determined.

Statistical Analysis

The Student’s t-test was used to determine the statistical differences between LDH measurements and IFN-γ secretion. ANOVA analysis was performed on BrdU results. Significance was taken at P values of < 0.05.

RESULTS

GCM Does Not Increase T-cell Cytotoxicity

We first tested if treating T-cells with CM from activated glioma cells (aGCM, the conditioned media from glioma cells that had been activated with supernatant from activated T-cells) or from non-activated CM (nGCM, the conditioned media from glioma cells that had been treated with supernatant from naïve T-cells) caused T-cell damage. At the
The supernatants from CD3/CD28 activated T-cells following treatment with all forms of GCM had the same effect on IFN-γ release, this suggests that glioma-secreted cytokines work together to effectively cause immunosuppression in T-cells or if they do work individually, it is through a mechanism separate from proliferation.

T-cell IFN-γ Secretion is Decreased by GCM

The supernatants from CD3/CD28 activated T-cells treated with either nGCM, aGCM, or 1%GCM (conditioned media from glioma cells incubated with 1% FBS) were tested for IFN-γ release. We observed a significant decrease in IFN-γ release from the CD3/CD28 T-cells following treatment with all forms of GCM, which was significantly lower than what was found in control T-cell IFN-γ release (Fig. 6). This suggests that glioma-secreted cytokines modify polarity of T-cells away from IFN-γ-secreting Th1 cells, thus reducing effective T-cell mediated immunity. Because all forms of GCM had the same effect on IFN-γ release, this response may be a base-line effect which is not affected by the immune properties of the T-cells.

DISCUSSION

Results from the present study help to elucidate several aspects of glioma-cytokine mediated immunosuppressive mechanisms. First, we have demonstrated that glioma released cytokines do not induce frank cytotoxicity in T-cells
and therefore this mechanism is not a likely candidate for glioma induction of immunosuppression. Since LDH release is an index of severe cell damage or death, current studies to measure more subtle effects on T-cell viability, such as measures of intracellular ATP levels or of mitochondrial function, need to be done to rule out low-levels of damage induced by GCMs. Second, our results indicate that proliferation suppression is a mechanism of glioma immunosuppression as seen with decreased proliferation of CD3/CD28 T-cells when incubated with increasing concentrations of GCM. This response, though, did not occur specifically with aGCM but occurred in nGCM as well. The proliferation inhibition response is therefore not a mechanism that is unique to glioma cells encountering active immunity and could therefore be a base-line glioma immunosuppressive mechanism. The fact that aGCM had an opposite effect on naïve T-cells (increase proliferation) compared to CD3/CD28 T-cells highlights how the immunological status of T-cells not only effects glioma response but also determines how they respond to glioma-secreted cytokines.

The combination of recombinant IL-10 and IGFBP decreased the proliferation of CD3-activated T-cells. In CD3/CD28 activated T-cells, IL-10/IGFBP showed a de-
crease as well, but at a concentration of 10ng/mL, suggesting that this concentration is either optimal for proliferation inhibition or IL-10/IGFBP are not as clearly involved in proliferation of CD3/CD28 activated T-cells as they are in CD-3 T-cells. This combination of cytokines is being further studied for their role in T-cell proliferation.

CD3/CD28 activated T-cells showed a decreased IFN-γ release when treated with increasing concentrations of 1% GCM, activated GCM and naïve GCM. Since IFN-γ is mainly secreted by Th1 cells [9] a decrease in IFN-γ release suggests a modification of the T-cell subtypes, although it is also possible that the GCM induces expression of anti-inflammatory mediators which reduce T-cell IFN-γ production (or secretion). These preliminary results suggest that T-cell differentiation may play a role in cytokine-induced immunosuppression of activated T-cells. This response was seen in all three conditions of GCM suggesting that the cytokines responsible for differentiation are secreted constitutively by glioma cells and are not affected by the immunological status of T-cells in the environment. Further studies of T-cell differentiation including flow-cytometry are currently underway.

When recombinant IL-10, TGF-β and IGFBP were incubated with T-cells individually, no significant patterns of T-cell proliferation or IFN-γ release were noted emphasizing the idea that cytokine-induced immunosuppression requires several cytokines working together. This has to be kept in mind when considering implementation of these mechanisms into treatment and that blocking individual cytokines (ie: TGF-β) is likely less effective than blocking several cytokines together. Currently explored mechanisms of cytokine-induced glioma immunosuppression have been restricted to the immunosuppressive properties of individual cytokines [5]. Suppression of TGF-β with antisense [4,8], TGF-β kinase inhibitors and other TGF-β antagonists were shown to be efficacious in several glioma models improving median survival [10] and reducing tumor volume [11], however the effects were limited. Further elaboration into TGF-β’s mechanism regarding synergistic cytokines and the mechanism of decreased cytotoxicity are necessary and could aid in future treatment protocols. In other studies, IL-10 was shown to decrease T-cell proliferation and to down-regulate MHC-II on monocytes [5-7]. Our preliminary data showed that IL-10 did not significantly suppress T-cell proliferation individually but did in combination with IGFBP. In previous studies we showed that IGFs and IGFBPs were important autocrine growth factors. IGFBP is expressed by many tumors and has been shown to regulate the availability of Insulin Growth Factors (IGF’s) [12]. We found that IGFBPs (specifically IGFBP-1) are preferentially expressed in glioma cell lines and are often found in CSF of glioma patients [12-15]. IGFBP is currently being considered as a marker for tumor and treatment [12-15]. Other cytokines (PGE2 and VEGF) have also been shown to regulate the immune response [4-8] but also with limited results. These studies are potentially confounded by the glioma’s expression of a variety of cytokines that work together to obtain immunosuppression. The blockade of any one cytokine may not be expected to have a significant impact and, as suggested by this study, it is important to first understand the immunosuppressive mechanisms of all collective glioma-secreted cytokines and then to elucidate the combinations of cytokines responsible for these mechanisms. This will increase the effectiveness of treatment by blocking all cytokines involved.

We recently reported encouraging preliminary results of an Immuno-Gene therapy tumor vaccine [16,17] as a treatment for malignant brain tumors. Mice with intracerebral glioma were treated with intratumoral injections of allogeneic fibroblasts genetically modified to secrete IL-2. Compared to control, these mice survived significantly longer. The intratumoral injection caused CD8 T-cell and natural killer cell mediated cytotoxicity in neoplastic cells only, not astrocytes or other non-neoplastic cells [16, 17]. Despite these encouraging results, the mice eventually developed significant tumors, which we attribute to tumor immunosuppression, possibly through the mechanisms elaborated above including suppression of proliferation and T-cell differentiation. With further elaboration of these immunosuppressive mechanisms and cytokines involved, we plan to modify our treatment to include the blockade of newly-found immunosuppressive cytokines and the modification of T-cell differentiation to Th1 and cytotoxic T-cells.

The major mechanisms involved in cytokine-induced immunosuppression described in this study include T-cell proliferation inhibition and T-cell differentiation. On an individual level, the cytokines studied were not enough to mimic the effects seen with GCM but a combination of two (IL-10 and IGFBP) showed similar results to GCM suggesting that T-cell proliferation and differentiation are more likely the product of several cytokines synergistically affecting T-cells. Further studies elaborating immunosuppressive mechanisms of the entire cytokine milieu as well as the identification of cytokine combinations responsible for immunosuppression are currently underway and will hopefully add to our arsenal of information used to treat glioma.

REFERENCES


Received: December 03, 2009 Revised: December 07, 2009 Accepted: September 09, 2010

© Ksendzovsky et al.; Licensee Bentham Open.

This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.